GCTK

Glucotrack

• Benzinga·5d ago

  12 Health Care Stocks Moving In Monday's Pre-Market Session

• NASDAQ·03/31 07:32

  Glucotrack FY25 Net Loss Narrows; Plans To Submit An IDE For CBGM In Q2 2026

• Benzinga·03/30 21:08

  GlucoTrack Q4 EPS $(3.97) Up From $(1.24 thousand) YoY

• Seeking Alpha·03/30 20:51

  Glucotrack GAAP EPS of -$31.22

• Reuters·03/30 20:50

  GlucoTrack FY25 net loss narrows to US$19.4 million; R&D expenses rise to US$9.8 million

• Reuters·03/30 20:50

  GLUCOTRACK REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

• Benzinga·03/30 17:05

  12 Health Care Stocks Moving In Monday's Intraday Session

• TipRanks·03/27 16:34

  Morning News Wrap-Up: 3/27/26: Today’s Biggest Stock Market Stories

• TipRanks·03/27 15:40

  GlucoTrack Prepares FDA Submission for Implantable CBGM Trial

• Benzinga·03/27 14:49

  GlucoTrack Stock Gains As Data Backs FDA Filing Plans For Glucose Monitoring Tech

• TipRanks·03/27 13:29

  Why is Glucotrack Stock (GCTK) Up Nearly 30% Today?

• TipRanks·03/27 12:34

  GlucoTrack to file IDE to FDA for continuous blood glucose monitoring technology

• Reuters·03/27 12:26

  GlucoTrack plans FDA IDE filing in Q2 2026; U.S. trial start expected in H2 2026 due to FDA review

• Benzinga·03/27 12:07

  Glucotrack To Submit IDE To FDA For Its Continuous Blood Glucose Monitoring Technology, With Goal To File Requisite Documents With FDA During Q2 Of 2026

• Benzinga·03/27 12:05

  12 Health Care Stocks Moving In Friday's Pre-Market Session